JANUARY 1 – MARCH 31, 2009
• Net sales for the period totaled SEK 16.9 M (15.6)
• Profit after tax was SEK 7.3 M (3.1) and earnings per share amounted to SEK 0.21 (0.09)
• Operating profit was SEK 9.9 M (3.6)
• Cash flow totaled SEK 8.7 M (neg: 5.5)
• The collaboration with Nucletron was extended in January with two new products for treatment planning
• The first product from the collaboration with TomoTherapy received FDA clearance in January and has been launched
AFTER THE CLOSE OF THE PERIOD
• The new VMAT product from the collaboration with Philips received FDA clearance and was launched in April
• A collaboration agreement with Siemens was signed in May
”We are very pleased to announce today a new partnership with Siemens. The agreement is of strategic importance for RaySearch as Siemens is one of the leading global suppliers of equipment for radiation therapy,” says Johan Löf, CEO of RaySearch
”Both revenues and profit increased during the first quarter. In addition, two new products have been launched on the market and several more are on the way, so I am very pleased with RaySearch’s current development”, concludes Johan Löf.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com
Financial Reports
